Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma

• ClinicalTrials.gov Identifier: NCT04322643
• Recruitment Status: Recruiting
• First Posted: March 26, 2020
• Last Update Posted: June 30, 2020
• Sponsor: Case Comprehensive Cancer Center
• Information provided by (Responsible Party): Case Comprehensive Cancer Center

Study Description

Brief Summary:

The purpose of this study is to test the safety and effectiveness of immunotherapy (checkpoint inhibitor therapy) in advanced bladder cancer when given intermittently. An unanswered question with the use of CPI (checkpoint inhibitor) is the duration of therapy required for optimal clinical benefit. In the absence of progressive disease or unacceptable toxicities, there are currently no specified criteria for treatment discontinuation. Strategies to reduce toxicity and maximize benefit require investigation. Thus, novel dosing schedules, early discontinuation considerations, and biomarkers of response are needed to identify patients who can sustain disease regression while off of therapy.

Condition or disease	Intervention/treatment	Phase
Urothelial Carcinoma	Drug: Pembrolizumab; Drug: Atezolizumab; Drug: Durvalumab; Drug: Nivolumab; Drug: Avelumab	Phase 2

Detailed Description:

A phase II study design to investigate the use of any CPI on an intermittent dosing schedule. Patients with advanced urothelial carcinoma (aUC) who treatment refractory or cisplatin ineligible will receive CPI of choice as per standard dosing. Patients who have initial >/=10% tumor burden reduction will discontinue the CPI until they experience a >/=20% disease progression following 24 weeks +/- 4 weeks of immunotherapy, at which time CPI therapy will be restarted.

All patients who do not meet criteria for the CPI intermittent phase of the study will be treated until unacceptable toxicity or RECIST-defined PD. Patients with RECIST-defined PD may continue CPI therapy at the discretion of the treating MD. These patients will continue with normal imaging every 12 weeks. In cases where a patient is continued on therapy after PD and develops subsequent PD (> 20% increase in sum of target lesions compared to the initial PD tumor measurements, the patient will come off study).

Patients who meet criteria for the intermittent phase (i.e., have >/=10% tumor burden reduction) will not receive CPI therapy. Imaging will continue per protocol (every 12 weeks from the initial date they stopped CPI therapy). Patients who have RECIST defined PD on the intermittent phase should reinitiate CPI therapy. Patients who have a subsequent decrease in tumor burden >/=10% can then restart CPI therapy as per protocol.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 20 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase II Study of Intermittent Checkpoint Inhibitor Therapy in Patients With Advanced Urothelial Carcinoma
• Actual Study Start Date: March 23, 2020
• Estimated Primary Completion Date: May 2021
• Estimated Study Completion Date: May 2021

Arms and Interventions

Arm

Intervention/treatment

Experimental: CPI therapy; Patients will be treated with CPI therapy for at least 24 weeks (+/- 4 weeks) as per standard of care (SOC), at which time those with a tumor burden reduction of 10% or greater will suspend CPI therapy.

Drug: Pembrolizumab; Pembrolizumab 200 mg IV over 30 minutes every 3 weeks; Other Name: KEYTRUDA; Drug: Atezolizumab; Atezolizumab 1200 mg IV over 60 minutes every 3 weeks. (if first dose is tolerated, all subsequent infusions may be delivered over 30 minutes); Other Name: TECENTRIQ; Drug: Durvalumab; Durvalumab 10 mg/kg IV over 60 minutes every 2 weeks.; Other Name: IMFINZI; Drug: Nivolumab; Nivolumab 480mg IV over 30 minutes every 4 weeks; Other Name: OPDIVO; Drug: Avelumab; Avelumab 800 mg IV over 60 minutes every 2 weeks; Other Name: BAVENCIO

Outcome Measures

Primary Outcome Measures :

1. Number of participants that sustain a response post CPI suspension [ Time Frame: at 36 weeks post CPI suspension ]
   Efficiency, as measured by number of participants that sustain a response post CPI suspension. Response is defined as tumor burden reduction of 10% or greater.

Secondary Outcome Measures :

1. Median Treatment Free Interval (TFI) in months [ Time Frame: up to 36 weeks from end of treatment, an average of 24 weeks ]
   Median and range TFI in months. Participants will be treated with CPI therapy for at least 24 weeks (+/- 4 weeks) as per standard of care (SOC), at which time those with a tumor burden reduction of 10% or greater will suspend CPI therapy. Participants with a documented increase in ≥ 20% tumor burden (RECIST 1.1 PD) will re-initiate CPI. For those patients who continue to have response, they will remain off therapy.
2. Overall response rate (ORR) [ Time Frame: up to 36 weeks from end of treatment, an average of 24 weeks ]
   Response to re-initiation of CPI therapy as measured by overall response rate (ORR) defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) as assessed by RECIST 1.1
3. Progression free survival (PFS) [ Time Frame: up to 36 weeks from end of treatment, an average of 24 weeks ]
   Progression free survival (PFS) defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first as assessed by RECIST 1.1 criteria. PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm and the appearance of ≥1 new lesions is also considered PD.
4. Overall Survival (OS) [ Time Frame: up to 36 weeks from end of treatment, an average of 24 weeks ]
   Overall Survival (OS) defined as the time from randomization to death due to any cause

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Men and women ≥ 18 years of age.
• Histological confirmation of urothelial carcinoma (any histology)
• Advanced or metastatic urothelial carcinoma.
• Measurable disease as defined by RECIST 1.1 criteria
• Has received at least 24 weeks (+/- 4 weeks) on CPI therapy per standard of care (SOC) for advanced urothelial carcinoma
• Karnofsky Performance Score (KPS) ≥70% (for more information on KPS, please see: http://www.npcrc.org/files/news/karnofsky_performance_scale.pdf)
• Willing and able to provide informed consent.

• Laboratory criteria for study entry must meet the following criteria:

  • Serum creatinine ≤ 2 x ULN OR CrCl ≥ 30 mL/min (measured or calculated using the Cockcroft-Gault formula).
  • Hb ≥ 8.0g/dL
  • AST and ALT ≤ 3.0 x ULN
  • Bilirubin ≤ 1.5 x ULN (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL)

Exclusion Criteria:

• History of severe hypersensitivity reaction to any monoclonal antibody.
• Patients are excluded if they have known HIV/AIDS.
• Major surgery (eg, cystectomy) less than 28 days prior to the first dose of study drug.
• Any condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 7 days prior to the first dose of study drug. Inhaled steroids and adrenal replacement steroid doses > 10 mg daily prednisone equivalent are permitted in the absence of active autoimmune disease.
• Known medical condition (eg, a condition associated with diarrhea or acute diverticulitis) that, in the investigator's opinion, would increase the risk associated with study participation or study drug administration or interfere with the interpretation of safety results.
• Pregnant women are excluded from this study because animal studies have demonstrated that PD-1/PD-L1 inhibitors can cause fetal harm when administered to pregnant women. Breastfeeding women are excluded from this study because PD-1/PD-L1 inhibitors may be excreted in human milk and the potential for serious adverse reactions in nursing infants.

Contacts and Locations

Contacts

Contact: Moshe Ornstein, MD; 1-866-223-8100; TaussigResearch@ccf.org

Locations

United States, Ohio

Cleveland Clinic, Case Comprehensive Cancer Center; Recruiting

Cleveland, Ohio, United States, 44195

Contact: Moshe Ornstein, MD 866-223-8100 TaussigResearch@ccf.org

Principal Investigator: Moshe Ornstein, MD

Sponsors and Collaborators

Case Comprehensive Cancer Center

Investigators

• Principal Investigator: Moshe Ornstein, MD; Cleveland Clinic, Case Comprehensive Cancer Center

More Information

• Responsible Party: Case Comprehensive Cancer Center
• ClinicalTrials.gov Identifier: NCT04322643
• Other Study ID Numbers: CASE6819
• First Posted: March 26, 2020
• Last Update Posted: June 30, 2020
• Last Verified: June 2020

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No
• Plan Description: Summary results are shared in publications

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Carcinoma; Carcinoma, Transitional Cell; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Pembrolizumab; Nivolumab; Durvalumab; Atezolizumab; Antineoplastic Agents, Immunological; Antineoplastic Agents